Fexapotide (trifluoroacetate) is a peptide.1 It induces apoptosis in LNCaP prostate cancer cells when used at a concentration of 2.5 mg/ml. Intraprostatic administration of fexapotide triflutate (0.6 mg/animal per week) reduces the numbers of prostate glandular epithelial cells without affecting other cell types and decreases prostate volume in rats.WARNING This product is not for human or veterinary use.
